Fig. 9: BSA- and SARS-CoV-2 RBD-specific total IgG titres induced by subcutaneous immunisation.
From: A synthetic cyclic peptide for promoting antigen presentation and immune activation
a BSA-specific total IgG titres (log 10) following primary immunisation and two boosts, as determined by ELISA. b SARS-COV-2 RBD-specific total IgG titres (log 10) following primary immunisation and one boost, as determined by ELISA. Mice (n = 5 per group) were immunised with the vaccine candidates (Table S1). VC-24 mice each received a physical mixture of BSA (20 μg), BB4 (2.5 μg) and BB6 (2.8 μg) in PBS (50 μL). Positive control mice each received BSA (20 μg) emulsified in CFA and PBS (1:1, total 50 μL). VC-25 mice each received a physical mixture of SARS-CoV-2 RBD (12.5 μg), BB4 (5.9 μg) and BB6 (6.6 μg) in PBS (50 μL). Positive control mice each received SARS-CoV-2 RBD (12.5 μg) emulsified in CFA and PBS (1:1, total 50 μL). Each point represents an individual mouse, with bars indicating the average antigen-specific serum IgG antibody titres. Statistical analysis was performed using a one-way ANOVA followed by Tukey post-hoc test (*, p < 0.05; ****, p < 0.0001).
